Your browser is no longer supported. Please, upgrade your browser.
Settings
SAGE Sage Therapeutics, Inc. daily Stock Chart
SAGE [NASD]
Sage Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.25 Insider Own2.40% Shs Outstand46.14M Perf Week-5.44%
Market Cap7.17B Forward P/E- EPS next Y-8.81 Insider Trans-30.21% Shs Float44.11M Perf Month8.12%
Income-287.90M PEG- EPS next Q-1.89 Inst Own96.69% Short Float5.87% Perf Quarter-7.25%
Sales- P/S- EPS this Y-49.30% Inst Trans8.31% Short Ratio5.77 Perf Half Y62.75%
Book/sh23.90 P/B6.50 EPS next Y1.70% ROA-53.00% Target Price206.29 Perf Year127.92%
Cash/sh23.48 P/C6.61 EPS next 5Y- ROE-57.70% 52W Range59.57 - 195.97 Perf YTD-5.69%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.74% Beta3.08
Dividend %- Quick Ratio28.90 Sales past 5Y- Gross Margin- 52W Low160.75% ATR7.65
Employees257 Current Ratio28.90 Sales Q/Q- Oper. Margin- RSI (14)45.76 Volatility5.43% 4.55%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.50% Profit Margin- Rel Volume0.62 Prev Close158.17
ShortableYes LT Debt/Eq0.00 EarningsMay 03 BMO Payout- Avg Volume448.51K Price155.33
Recom1.70 SMA20-2.30% SMA50-2.05% SMA20022.25% Volume277,730 Change-1.80%
Mar-26-18Resumed Canaccord Genuity Buy $210
Feb-26-18Initiated Morgan Stanley Overweight
Dec-08-17Reiterated Needham Buy $100 → $193
Dec-08-17Reiterated Canaccord Genuity Buy $140 → $191
Dec-07-17Reiterated Chardan Capital Markets Buy $140 → $225
Nov-10-17Upgrade Chardan Capital Markets Neutral → Buy $60 → $140
Nov-10-17Reiterated Needham Buy $86 → $100
Oct-06-17Resumed Goldman Buy $87
Sep-15-17Initiated RBC Capital Mkts Outperform $117
Sep-13-17Reiterated Needham Buy $95 → $86
Aug-09-17Resumed Stifel Buy $104
May-16-17Initiated Needham Buy $82
May-12-17Initiated BofA/Merrill Buy $85
Feb-22-17Downgrade H.C. Wainwright Buy → Neutral $56 → $76
Feb-14-17Upgrade Chardan Capital Markets Sell → Neutral $60
Dec-14-16Upgrade Raymond James Outperform → Strong Buy $84
Nov-14-16Initiated Stifel Buy $90
Oct-04-16Resumed Leerink Partners Outperform $68
Sep-13-16Initiated Raymond James Outperform $75
Jun-23-16Initiated H.C. Wainwright Buy $56
May-24-18 11:34AM  Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today Motley Fool
May-23-18 06:30AM  Sage Therapeutics to Present at Bernsteins 34th Annual Strategic Decisions Conference Business Wire -5.16%
May-08-18 05:55PM  Edited Transcript of SAGE earnings conference call or presentation 3-May-18 12:00pm GMT Thomson Reuters StreetEvents
06:30AM  Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference Business Wire
May-03-18 04:01PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
06:30AM  Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness Business Wire
Apr-26-18 05:08PM  CNBC's 2018 Stock Draft Round 3 CNBC Videos
Apr-24-18 06:30AM  Sage Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 3, 2018 Business Wire
Apr-23-18 08:15AM  Sage Therapeutics asks FDA to approve lead drug for postpartum depression American City Business Journals
07:00AM  Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression Business Wire
Apr-20-18 04:48PM  Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today Motley Fool -12.77%
10:01AM  A Winning Stock Picker's 8 Favorite Plays Investopedia
Apr-17-18 04:01PM  Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings Business Wire
Apr-05-18 10:19AM  FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus Zacks
Apr-04-18 04:01PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-28-18 04:15PM  Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug fairly CNBC
01:47PM  Sage CEO on post-partum depression, innovation for the co... CNBC Videos
Mar-20-18 11:41AM  Biotech short seller eviscerates Proteostasis in new report, dinging shares American City Business Journals
Mar-06-18 04:14PM  Biotech Jumps After Rival Pushes Back Depression Drug Tests Investor's Business Daily
12:58PM  Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today Motley Fool
Mar-05-18 04:01PM  Sage Therapeutics to Present at Cowen & Co. 38th Annual Health Care Conference Business Wire
Feb-27-18 11:30PM  Why Oppenheimer Global fund is focusing on biotech as rates rise Reuters
11:18PM  Why Oppenheimer Global fund is focusing on biotech as rates rise Reuters
11:00PM  Why Oppenheimer Global fund is focusing on biotech as rates rise Reuters
Feb-26-18 09:21AM  Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy Benzinga
08:20AM  Todays Research Reports on Trending Tickers: Sage Therapeutics and ACADIA Pharmaceuticals ACCESSWIRE
Feb-22-18 08:26PM  Edited Transcript of SAGE earnings conference call or presentation 22-Feb-18 1:00pm GMT Thomson Reuters StreetEvents -5.16%
06:30AM  Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update Business Wire
06:00AM  SAGE Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-20-18 08:16PM  Zogenix Inc. (ZGNX) and Arena Pharmaceuticals, Inc. (ARNA) Helped This Healthcare-Focused Fund Earn Double-Digit Returns Insider Monkey
08:20AM  Research Report Identifies Advanced Disposal Services, Opus Bank, Anworth Mortgage Asset, Exelon, Newell Brands, and Sage Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-13-18 06:30AM  Sage Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, February 22, 2018 Business Wire
Feb-12-18 04:01PM  Sage Therapeutics to Present at Leerink Partners 7th Annual Global Healthcare Conference Business Wire
08:20AM  Todays Research Reports on Stocks to Watch: Sarepta Therapeutics and Sage Therapeutics ACCESSWIRE
Feb-08-18 10:14PM  Sage Therapeutics Prices Public Offering of Common Stock Business Wire -6.39%
09:15AM  Gilead Sciences And Sage Therapeutics Just Picked Up Big FDA Decisions Market Exclusive
Feb-07-18 04:01PM  Sage Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
06:30AM  Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder Business Wire
Feb-02-18 04:01PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
07:20AM  Blog Exposure - Sage Therapeutics Declared Positive Results from Phase-1/2 Clinical Trial of SAGE-217 in Treatment of Insomnia ACCESSWIRE
Feb-01-18 05:34PM  Sage Therapeutics Wants to Show Its Treatment Can Help People Sleep GuruFocus.com
Jan-31-18 04:25PM  Sage Therapeutics Just Popped To A Record High Here's Why Investor's Business Daily
06:00AM  Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders Business Wire
Jan-28-18 11:34AM  3 Small Biotechs That Big Drugmakers Are Probably Drooling Over Motley Fool
Jan-08-18 07:00AM  Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company Business Wire
Jan-03-18 04:15PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-02-18 04:30PM  Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 Business Wire
03:17PM  Best Biotech Stock Trades and Mergers to Watch in 2018 TheStreet.com
Dec-29-17 03:16PM  7 Notable Biotechs With Data Expected By Year's End Benzinga
Dec-28-17 12:05PM  Sage Therapeutics CEO cashes in $35M worth of stock options American City Business Journals
Dec-22-17 06:15PM  Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $35.1 million of Shares GuruFocus.com +6.75%
Dec-14-17 09:51AM  10 Biggest Antidepressant Drug Companies In 2017 Insider Monkey
Dec-13-17 07:31AM  5 Biotech Buyout Candidates for 2018 Motley Fool
06:00AM  Why Biotech Sage Therapeutics May Keep Soaring Investopedia
Dec-11-17 08:36AM  Sage Therapeutics Soars: Stock Adds 7.1% in Session Zacks
Dec-08-17 04:59PM  Why Chicago Bridge & Iron, Teva Pharmaceutical Industries, and Sage Therapeutics Jumped Today Motley Fool +7.08%
03:42PM  Gene therapy stocks to watch CNBC Videos
01:33PM  Sage CEO hopes experimental depression drug will be as big as Prozac CNBC
01:23PM  Sage Therapeutics takes on major depressive disorder CNBC Videos
08:34AM  Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Sage Therapeutics and Nektar Therapeutics ACCESSWIRE
07:38AM  Sage Therapeutics shares gain another 2% as SunTrust raises stock price target to $178 vs. $116 MarketWatch
06:56AM  Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug MarketWatch
Dec-07-17 06:00PM  Why Sage Therapeutics Gained 70% Today Motley Fool +70.04%
05:05PM  What Happened in the Stock Market Today Motley Fool
05:02PM  Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference Business Wire
04:32PM  Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday Motley Fool
04:24PM  Sage Therapeutics, Dollar General jump; LendingClub tumbles Associated Press
04:08PM  This Biotech Catapults 70% Higher On Depression Drug Results Investor's Business Daily
04:06PM  3 Stocks Gain on Thursday GuruFocus.com
03:52PM  Sage soars on mid-phase depression drug trial CNBC Videos
02:41PM  Cowen Raises Sage Value On New Phase 2 Trial Success Benzinga
02:10PM  Sage Therapeutics Rises 70% on Strong Phase 2 Results GuruFocus.com
12:57PM  Charting the Market: Sage Therapeutics Could Cure Your Blues Barrons.com
10:55AM  With latest drug trial, Sage catapults into top 5 most valuable Mass. biotechs American City Business Journals
09:55AM  SAGE Therapeutics Inc (SAGE) Shines on Encouraging Clinical Data SmarterAnalyst
09:26AM  Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers TheStreet.com
09:11AM  UPDATE: Sage Therapeutics shares soar more than 74% on positive trial of depression treatment MarketWatch
09:03AM  Biotech Sage Therapeutics skyrockets more than 70 percent after depression drug breakthrough CNBC
08:42AM  Stocks making the biggest moves premarket: SHAK, AVGO, EXPE, PCLN & more CNBC
06:42AM  Sage's depression drug succeeds in mid-stage study, shares soar Reuters
06:19AM  Sage's depression drug succeeds in mid-stage study Reuters
06:00AM  Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder Business Wire
Dec-04-17 04:01PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
08:05AM  Factors of Influence in 2018, Key Indicators and Opportunity within Exelon, Newell Brands, Sage Therapeutics, Advanced Disposal Services, Opus Bank, and Anworth Mortgage Asset New Research Emphasizes Economic Growth GlobeNewswire
Nov-30-17 03:38PM  SAGE Therapeutics, Inc. Fundamental Analysis : November 30, 2017 Capital Cube
Nov-22-17 08:00AM  Todays Research Reports on Stocks to Watch: Sage Therapeutics and GW Pharmaceuticals ACCESSWIRE +6.12%
Nov-17-17 04:01PM  Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares Business Wire
02:43PM  Why Biotech Sage Therapeutics Is Overvalued Investopedia
Nov-14-17 09:00PM  Sage Therapeutics Prices Public Offering of Common Stock Business Wire -6.76%
03:03PM  7 Life Science Stocks to Buy Today InvestorPlace
Nov-13-17 04:01PM  Sage Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Nov-11-17 03:15PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Nov-10-17 03:05PM  Likely FDA approval for postpartum depression drug pushes Sage Therapeutics stock up 40% CNBC
01:35PM  Sage Therapeutics takes on postpartum depression with tri... CNBC Videos
08:10AM  Todays Research Reports on Stocks to Watch: Aralez Pharmaceuticals and Sage Therapeutics ACCESSWIRE
06:56AM  Sage Therapeutics stock bounces 54% after positive results for depression treatment MarketWatch
Nov-09-17 05:36PM  Sage Therapeutics Hits Record On Potential $600 Million Depression Drug Investor's Business Daily +54.25%
12:40PM  2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why. Motley Fool
10:03AM  New Drug Eases Postpartum Depression In Victory For Tiny Sage Therapeutics Forbes
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which has completed Phase II clinical trials for the treatment of PPD, major depressive disorders, bipolar depression, Parkinson's disease, and sleep disorders; and SAGE-718, an oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of depression, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, Huntington's disease, and neuropathic pain. In addition, its product pipeline comprises SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and product pipeline that are in preclinical stage includes SAGE-689 and SAGE-105 novel GABAA receptor modulators The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRATES JAMES MDirectorMay 08Option Exercise8.927,00062,44012,000May 08 04:51 PM
FRATES JAMES MDirectorMay 08Sale154.007,0001,078,0005,000May 08 04:51 PM
IGUCHI KIMICFO & TreasurerApr 25Sale140.7511,0181,550,81038,345Apr 25 05:44 PM
IGUCHI KIMICFO & TreasurerApr 24Sale142.845,000714,18549,363Apr 25 05:44 PM
IGUCHI KIMICFO & TreasurerApr 23Sale144.4812,1351,753,30254,363Apr 25 05:44 PM
STARR KEVIN PDirectorApr 18Sale168.2824,0004,038,650302,817Apr 19 04:35 PM
STARR KEVIN PDirectorApr 17Sale169.2535,0005,923,600326,817Apr 19 04:35 PM
PAUL STEVEN MDirectorMar 06Sale172.0058,1399,999,908632,712Mar 08 04:02 PM
Kanes StephenChief Medical OfficerJan 12Option Exercise0.4520,0009,00022,948Jan 12 04:07 PM
Kanes StephenChief Medical OfficerJan 10Sale177.1844,0007,795,8372,948Jan 12 04:07 PM
JONAS JEFFREY MPresident & CEODec 26Option Exercise0.4550,00022,50051,226Dec 26 04:34 PM
JONAS JEFFREY MPresident & CEODec 22Option Exercise0.4512,7535,73913,979Dec 22 04:02 PM
JONAS JEFFREY MPresident & CEODec 22Sale155.0012,7531,976,7151,226Dec 22 04:02 PM
JONAS JEFFREY MPresident & CEODec 21Option Exercise0.45110,24749,611211,473Dec 22 04:02 PM
JONAS JEFFREY MPresident & CEODec 21Sale157.45210,24733,102,6611,226Dec 22 04:02 PM
Robichaud AlbertChief Scientific OfficerDec 14Sale159.4360,0009,565,95794,259Dec 14 06:51 PM